Esperion Therapeutics (NASDAQ:ESPR) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $8.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Esperion Therapeutics’ FY2024 earnings at ($0.27) EPS.

A number of other equities analysts have also issued reports on ESPR. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.30.

Esperion Therapeutics Stock Up 0.5 %

ESPR stock opened at $2.17 on Tuesday. The stock has a market capitalization of $427.57 million, a PE ratio of -3.39 and a beta of 1.01. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The firm has a 50 day moving average of $2.41 and a 200 day moving average of $2.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ESPR. Eaton Financial Holdings Company LLC acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at about $73,000. Barclays PLC grew its holdings in Esperion Therapeutics by 99.6% in the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 154,509 shares during the period. Geode Capital Management LLC increased its position in shares of Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $606,000. Finally, Anson Funds Management LP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $540,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.